Patents by Inventor James Sligh

James Sligh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050091704
    Abstract: Described are methods for inactivating adenine nucleotide transporter proteins in specific tissues of a transgenic nonhuman animal using a conditional knockin/knockout technology such as the Cre-LoxP, Flip-FLP recombinase, or Tet-on/off technologies. Specifically, the Ant2 gene is functionally inactivated in a mouse in liver, with or without the concurrent inactivation of the Ant1 gene. The result is an animal in which the Ant2 gene and accompanying ANT2 protein is absent in one or more tissues, either in the presence or absence of the Ant1 gene and accompanying ANT1 protein. The resulting animals, cells, mitochondria, and subcelluar fractions such as the mitochondrial permeability transition pore can then be used to identify agents that affect animal and/or subcellular function via a direct or indirect interaction with the ANT2 protein and/or its Ant2 gene.
    Type: Application
    Filed: September 2, 2003
    Publication date: April 28, 2005
    Applicant: Emory University
    Inventors: Douglas Wallace, Grant MacGregor, Katrina Waymire, Shawn Levy, James Sligh, Jason Kokoszka
  • Patent number: 5602307
    Abstract: A transgenic mouse which contains a predefined, specific and desired alteration in at least one of its two chromosomal alleles of a cellular adhesion gene, such that at least one of these alleles contains a mutation which alters the expression of the allele.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: February 11, 1997
    Assignee: Baylor College of Medicine
    Inventors: Arthur L. Beaudet, Raymond Wilson, Allan Bradley, William E. O'Brien, James Sligh, Christie Ballantyne, Daniel Bullard